Biotech Trial Starts Rebound to 5,318 in 2024 as Sector Nears Pre-Covid Recovery

1 articles · Updated · CNBC · Jul 14

Global industry-sponsored clinical trial starts held at 5,318 in 2024, essentially matching 2019's 5,316 after declines in 2022 and 2023.
That stabilization points to a broader biotech recovery as funding conditions improve, AI speeds drug discovery and development, and U.S. healthcare company activity rises.
Large pharmaceutical companies also face looming patent expirations, a pressure that could drive acquisitions of new drugs and technologies and lift biotech valuations.
The report highlights IQVIA, Danaher and Vertex Pharmaceuticals as ways to play the rebound, arguing each still trades below or reasonably against historical valuations despite durable competitive positions.

Sources

Left100%

With big pharma spending billions on acquisitions, has the window for finding undervalued biotech gems already closed for investors?

As AI fuels a biotech boom, could powerful pharmacy middlemen prevent patients from accessing cheaper, life-saving drugs?

The EU is fast-tracking biotech with new laws, so why is the U.S. falling behind in modernizing its regulations?

1 total

Left100%